JP7422473B2 - 合成方法 - Google Patents

合成方法 Download PDF

Info

Publication number
JP7422473B2
JP7422473B2 JP2022526073A JP2022526073A JP7422473B2 JP 7422473 B2 JP7422473 B2 JP 7422473B2 JP 2022526073 A JP2022526073 A JP 2022526073A JP 2022526073 A JP2022526073 A JP 2022526073A JP 7422473 B2 JP7422473 B2 JP 7422473B2
Authority
JP
Japan
Prior art keywords
compound
formula
stage
formula iii
liald
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022526073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500532A (ja
JPWO2021089873A5 (https=
JP2023500532A5 (https=
Inventor
ランズ，ピーター
ナイト，ジョージ
チャブ，リチャード
ロンデスブラフ，デリク
ベンウェイ，ティファニー
ジョエル，ゼラ
Original Assignee
サイビン ユーケー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1916210.6A external-priority patent/GB201916210D0/en
Priority claimed from GBGB1917320.2A external-priority patent/GB201917320D0/en
Priority claimed from GB2008303.6A external-priority patent/GB2585978B/en
Application filed by サイビン ユーケー リミテッド filed Critical サイビン ユーケー リミテッド
Publication of JP2023500532A publication Critical patent/JP2023500532A/ja
Publication of JPWO2021089873A5 publication Critical patent/JPWO2021089873A5/ja
Publication of JP2023500532A5 publication Critical patent/JP2023500532A5/ja
Application granted granted Critical
Publication of JP7422473B2 publication Critical patent/JP7422473B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022526073A 2019-11-07 2020-11-09 合成方法 Active JP7422473B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1916210.6 2019-11-07
GBGB1916210.6A GB201916210D0 (en) 2019-11-07 2019-11-07 High purity tryptamines and methods of synthesis thereof
GB1917320.2 2019-11-28
GBGB1917320.2A GB201917320D0 (en) 2019-11-28 2019-11-28 Novel compounds
GB2008303.6A GB2585978B (en) 2019-06-03 2020-06-02 Therapeutic compositions
GB2008303.6 2020-06-02
PCT/EP2020/081503 WO2021089873A1 (en) 2019-11-07 2020-11-09 Method of synthesis

Publications (4)

Publication Number Publication Date
JP2023500532A JP2023500532A (ja) 2023-01-06
JPWO2021089873A5 JPWO2021089873A5 (https=) 2023-02-02
JP2023500532A5 JP2023500532A5 (https=) 2023-02-02
JP7422473B2 true JP7422473B2 (ja) 2024-01-26

Family

ID=75849570

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022526073A Active JP7422473B2 (ja) 2019-11-07 2020-11-09 合成方法
JP2022526074A Active JP7423131B2 (ja) 2019-11-07 2020-11-09 化合物
JP2023202672A Active JP7748437B2 (ja) 2019-11-07 2023-11-30 化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022526074A Active JP7423131B2 (ja) 2019-11-07 2020-11-09 化合物
JP2023202672A Active JP7748437B2 (ja) 2019-11-07 2023-11-30 化合物

Country Status (18)

Country Link
US (6) US11643390B2 (https=)
EP (3) EP3873883B1 (https=)
JP (3) JP7422473B2 (https=)
KR (2) KR20220082092A (https=)
CN (2) CN114829341B (https=)
AU (2) AU2020378647B2 (https=)
BR (1) BR112022008919A2 (https=)
CA (2) CA3160337C (https=)
DK (1) DK3844147T3 (https=)
ES (2) ES2940811T3 (https=)
HR (2) HRP20220797T1 (https=)
HU (2) HUE059403T2 (https=)
IL (2) IL292754B2 (https=)
MX (1) MX2022005399A (https=)
NZ (1) NZ788543A (https=)
PL (2) PL3873883T3 (https=)
PT (2) PT3873883T (https=)
WO (2) WO2021089873A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
JP7422473B2 (ja) * 2019-11-07 2024-01-26 サイビン ユーケー リミテッド 合成方法
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
US11332441B2 (en) * 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
AU2021204158B2 (en) * 2020-06-02 2023-03-02 Cybin Uk Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
EP3902541B1 (en) * 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
WO2021250435A1 (en) 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
IL308816A (en) 2021-05-25 2024-01-01 Atai Therapeutics Inc New n,n-dimethyltryptamine salts and crystalline salt forms
MX2023014620A (es) 2021-06-09 2024-01-30 Atai Therapeutics Inc Nuevos profarmacos y conjugados de dimetiltriptamina.
EP4122916A1 (en) * 2021-07-22 2023-01-25 GH Research Ireland Limited Method for preparing an organic compound
KR20240132439A (ko) * 2021-07-22 2024-09-03 지에이치 리서치 아일랜드 리미티드 트립타민 유도체의 제조 방법
US11697638B2 (en) * 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
MX2024005955A (es) 2021-11-18 2024-06-11 Cybin Uk Ltd Formulaciones inyectables e inhalables.
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
WO2023108174A1 (en) * 2021-12-10 2023-06-15 Terran Biosciences, Inc. Analogs of 6-methoxy- n, n-dimethyltryptamine
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス， インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
WO2023147423A1 (en) * 2022-01-28 2023-08-03 Miralogx Llc Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US20230346718A1 (en) * 2022-04-27 2023-11-02 Yale University Method of treating, ameliorating and/or preventing depression
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US12264131B2 (en) * 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
CN120344243A (zh) 2022-10-13 2025-07-18 赛本英国有限公司 包含致幻剂的胃肠外制剂的施用方法
EP4618981A1 (en) 2022-11-17 2025-09-24 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
TW202430149A (zh) * 2022-12-01 2024-08-01 美商雅特益醫療公司 Ｎ，ｎ－二甲基色胺之結晶形式及其使用方法
WO2024156713A1 (en) 2023-01-23 2024-08-02 Cybin Uk Ltd Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent
AU2024242138A1 (en) 2023-03-31 2025-11-13 Cybin Uk Ltd Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
US12157722B1 (en) * 2023-08-03 2024-12-03 Gilgamesh Pharmaceuticals, Inc. Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12129234B1 (en) * 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
WO2026013174A1 (en) 2024-07-10 2026-01-15 Cybin Uk Ltd Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016181414A1 (en) 2015-05-12 2016-11-17 Council Of Scientific & Industrial Research Process for the synthesis of ivacaftor and related compounds

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336378A (en) 1980-04-10 1982-06-22 Sandoz, Inc. Isoxazolyl indolamines
EP0593513B1 (en) * 1991-06-21 1998-10-28 Smithkline Beecham Plc Tryptamine analogues, their synthesis and their use as 5-ht1-like receptors or 5-ht2 receptor agonistes
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
EP2036540A3 (en) 2000-06-16 2009-12-16 Jagotec AG Improved injectable dispersions of propofol
WO2004085392A1 (en) 2003-03-25 2004-10-07 Faust Pharmaceuticals Melatonin derivatives and their use for treating neurological dysfunctions
JP2010507585A (ja) 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
CZ302424B6 (cs) * 2007-06-13 2011-05-11 Zentiva, A. S. Zpusob prípravy almotriptanu o vysoké cistote
MX2010001390A (es) * 2007-08-06 2010-08-02 Synosia Therapeutics Inc Métodos para el tratamiento de dependencia.
US20090076121A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched sumatriptan
US20090093513A1 (en) 2007-10-09 2009-04-09 Hamann Mark T Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter
US20100113496A1 (en) 2008-09-25 2010-05-06 Auspex Pharmaceuticals, Inc. Piperidine modulators of vmat2
EP2771341A4 (en) 2011-10-28 2015-09-23 Univ Texas NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
MX370188B (es) * 2013-03-14 2019-12-04 Dart Neuroscience Cayman Ltd Compuestos de piridina y pirazina sustituidos como inhibidores de pde4.
EP3628640B1 (en) 2014-09-02 2023-08-09 Hub Therapeutics Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
WO2018064465A1 (en) * 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
WO2019089902A1 (en) 2017-11-01 2019-05-09 Drexel University Compounds, compositions, and methods for treating diseases
MD3927338T2 (ro) 2019-02-22 2025-03-31 Gh Res Ireland Limited Compoziții cuprinzând 5-metoxi-N,N-dimetiltriptamină (5-MeO-DMT) pentru utilizare în tratarea tulburărilor mentale
EP4353314A3 (en) 2019-02-22 2024-07-03 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression
AU2020228289B2 (en) * 2019-02-27 2026-02-05 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
CN113784962B (zh) 2019-02-27 2025-04-25 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
JP7422473B2 (ja) 2019-11-07 2024-01-26 サイビン ユーケー リミテッド 合成方法
CN111072492A (zh) * 2019-11-29 2020-04-28 浙江工业大学 一种合成3,4-二氯-2-氨基-5-氟联苯的方法
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
WO2021234608A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
EP3902541B1 (en) 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
GB202008961D0 (en) 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
CN116056705A (zh) 2020-08-05 2023-05-02 巴塞尔大学医院 用于dmt辅助心理疗法的静脉内dmt施用方法
WO2022043227A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US20220062237A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
JP2023544724A (ja) 2020-10-02 2023-10-25 サイビン アイアールエル リミテッド 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
WO2022117640A1 (en) 2020-12-01 2022-06-09 Small Pharma Ltd Inhalable formulations
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
IL303288A (en) 2020-12-01 2023-07-01 Small Pharma Ltd N,N-Dimethyltryptamine compounds partially or fully deuterated
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016181414A1 (en) 2015-05-12 2016-11-17 Council Of Scientific & Industrial Research Process for the synthesis of ivacaftor and related compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CELIK, L et al.，Binding of Serotonin to the Human Serotonin Transporter. Molecular Modeling and Experimental Validation，Journal of the American Chemical Society，2008年，Vol.130, No.12，p.3853-3865，Supporting Information (Binding of Serotonin to the Human Serotonin Transporter. Molecular Modeling and Experimental Support), S1-S14
MORRIS, P E, Jr et al.，INDOLEALKYLAMINE METABOLISM: SYNTHESIS OF DEUTERATED INDOLEALKYLAMINES AS METABOLIC PROBES，Journal of Labelled Compounds and Radiopharmaceuticals，1993年，Vol.33, No.6，p.455-466
有機合成用 縮合剤カタログ，富士フイルム 和光純薬株式会社，2018年，第2版，p.1-15

Also Published As

Publication number Publication date
US20220281818A1 (en) 2022-09-08
US12084417B2 (en) 2024-09-10
CN114829340A (zh) 2022-07-29
HUE059403T2 (hu) 2022-11-28
HUE061482T2 (hu) 2023-07-28
US12157723B2 (en) 2024-12-03
US20230250059A1 (en) 2023-08-10
IL292754B2 (en) 2025-12-01
PL3844147T3 (pl) 2022-07-18
PT3844147T (pt) 2022-07-04
IL292753B1 (en) 2023-09-01
KR20230142817A (ko) 2023-10-11
MX2022005399A (es) 2022-07-05
EP3873883B1 (en) 2022-12-21
JP7748437B2 (ja) 2025-10-02
CN114829341A (zh) 2022-07-29
WO2021089873A1 (en) 2021-05-14
PT3873883T (pt) 2023-03-24
JP7423131B2 (ja) 2024-01-29
US20210395201A1 (en) 2021-12-23
PL3873883T3 (pl) 2023-05-08
WO2021089872A1 (en) 2021-05-14
BR112022008919A2 (pt) 2022-08-09
CN114829340B (zh) 2023-12-12
IL292753B2 (en) 2024-01-01
US11643390B2 (en) 2023-05-09
IL292753A (en) 2022-07-01
JP2024028798A (ja) 2024-03-05
EP3873883A1 (en) 2021-09-08
JP2023500532A (ja) 2023-01-06
AU2020381103B2 (en) 2022-08-11
CA3160337A1 (en) 2021-05-14
ES2940811T3 (es) 2023-05-11
US20240217929A1 (en) 2024-07-04
AU2020378647A1 (en) 2022-06-09
IL292754B1 (en) 2025-08-01
CA3160334C (en) 2024-04-30
US20250042852A1 (en) 2025-02-06
EP3844147B1 (en) 2022-04-06
IL292754A (en) 2022-07-01
EP4180037A1 (en) 2023-05-17
DK3844147T3 (da) 2022-07-04
AU2020381103A1 (en) 2022-06-09
US11578039B2 (en) 2023-02-14
AU2020378647B2 (en) 2023-06-15
HRP20220797T1 (hr) 2022-10-14
ES2920681T3 (es) 2022-08-08
CN114829341B (zh) 2024-03-08
HRP20230281T1 (hr) 2023-04-28
KR20220082092A (ko) 2022-06-16
US20230167056A1 (en) 2023-06-01
EP3844147A1 (en) 2021-07-07
CA3160334A1 (en) 2021-05-14
NZ788543A (en) 2022-10-28
CA3160337C (en) 2023-08-29
JP2022546635A (ja) 2022-11-04

Similar Documents

Publication Publication Date Title
JP7422473B2 (ja) 合成方法
TWI891942B (zh) 氘化化合物
CN116056763B (zh) 包含氘代或部分氘代的n,n-二甲基色胺化合物的治疗组合物
HK40060666A (en) Method of synthesis
HK40060666B (en) Method of synthesis
HK40056359A (en) Compounds
HK40056359B (en) Compounds
EA049402B1 (ru) Соединения
GB2605144A (en) Deuterated compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230124

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240111

R150 Certificate of patent or registration of utility model

Ref document number: 7422473

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350